Genocea Biosciences (GNCA) Research Coverage Started at Robert W. Baird

Robert W. Baird started coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a report released on Monday. The brokerage issued an outperform rating and a $3.00 target price on the biotechnology company’s stock.

A number of other equities analysts have also recently weighed in on the stock. Piper Jaffray Companies reaffirmed an overweight rating and set a $5.00 price objective on shares of Genocea Biosciences in a research report on Thursday, November 2nd. Zacks Investment Research raised shares of Genocea Biosciences from a hold rating to a buy rating and set a $1.75 price objective for the company in a research report on Monday, October 16th. Finally, Needham & Company LLC raised shares of Genocea Biosciences from a hold rating to a buy rating and set a $3.00 price objective for the company in a research report on Tuesday, February 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $4.21.

Genocea Biosciences (NASDAQ GNCA) opened at $0.98 on Monday. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of 2.51. Genocea Biosciences has a 1 year low of $0.79 and a 1 year high of $7.29.

A number of hedge funds have recently modified their holdings of GNCA. Schwab Charles Investment Management Inc. purchased a new position in Genocea Biosciences in the 2nd quarter valued at approximately $257,000. Rhumbline Advisers purchased a new position in Genocea Biosciences in the 2nd quarter valued at approximately $157,000. Bank of New York Mellon Corp boosted its position in Genocea Biosciences by 594.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 84,119 shares of the biotechnology company’s stock valued at $439,000 after buying an additional 72,008 shares during the period. Teachers Advisors LLC purchased a new position in Genocea Biosciences in the 2nd quarter valued at approximately $268,000. Finally, TIAA CREF Investment Management LLC purchased a new position in Genocea Biosciences in the 2nd quarter valued at approximately $404,000. 12.03% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Genocea Biosciences (GNCA) Research Coverage Started at Robert W. Baird” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://weekherald.com/2018/02/15/genocea-biosciences-gnca-research-coverage-started-at-robert-w-baird.html.

About Genocea Biosciences

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Analyst Recommendations for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply